Protara Therapeutics, Inc.
TARA- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001359931
In the last 90 days, Protara Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 119 institutions reported holding it in 13F filings for Q2 2026, worth $176.2M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $882.2K in total
- 1
- 13F holdersQ2 2026, +8 vs. previous quarter
- 119
- 13F valueReported value at the end of Q2 2026
- $176.2M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding TARA, Q2 2026
No superinvestor reported holding TARA at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Protara Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 (view filing)4:10 PM ET | Jun 29 | 2 days | Shefferman JesseCEO and President | SSale | −215.7K | $4.09 | −$882.2K | −23.0%721.8K after | |
| Apr 9, 2026 (view filing) | Apr 8 | 1 day | Zummo JacquelineChief R&D Officer | SSale | −1.13K | $5.40 | −$6.12K | −1.2%94.8K after | |
| Apr 2, 2026 (view filing) | Apr 1 | 1 day | Zummo JacquelineChief R&D Officer | SSale | −22.6K | $5.26 | −$118.9K | −19.1%96.0K after | |
| May 19, 2025 (view filing) | May 14 | 5 days | Levy Richard SDirector | PPurchase | +20.0K | $3.19 | +$63.8K | +64.5%51.0K after | Amended |
| Mar 28, 2025 (view filing) | Mar 26 | 2 days | Zummo JacquelineChf Scientific Operations Off | SSale | −21.2K | $4.53 | −$96.1K | −17.7%98.9K after | 10b5-1 |
| Sep 12, 2024 (view filing) | Sep 11-12 | 1 day | Opaleye Management Inc.10% Owner | SSaleCommon Stock, par value $0.001 per share | −158.9K | $1.71 | −$271.7K | −77.9%45.0K after | 4 lots |
| Sep 10, 2024 (view filing) | Sep 9-10 | 1 day | Opaleye Management Inc.10% Owner | SSaleCommon Stock, par value $0.001 per share | −62.0K | $1.84 | −$114.1K | −53.9%53.1K after | 4 lots |
| Jul 18, 2024 (view filing) | Jul 16 | 2 days | Opaleye Management Inc.10% Owner | SSaleCommon Stock, par value $0.001 per share | −11.4K | $2.44 | −$27.8K | −16.8%56.5K after | 2 lots |
| Jul 11, 2024 (view filing) | Jul 9-11 | 2 days | Opaleye Management Inc.10% Owner | SSaleCommon Stock, par value $0.001 per share | −74.6K | $2.36 | −$175.7K | −55.4%60.0K after | 6 lots |
| Jul 3, 2024 (view filing) | Jul 1 | 2 days | Opaleye Management Inc.10% Owner | SSaleCommon Stock, par value $0.001 per share | −8.29K | $2.12 | −$17.6K | −8.7%87.5K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in Protara Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jupiter Topco LLC | 4,696,709 | $17.9M | 0.01% | +4,696,709 | New |
| BlackRock, Inc. | 3,663,499 | $14.0M | 0.00% | +268,531+7.9% | Added |
| Millennium Management LLC | 3,101,166 | $11.8M | 0.01% | +269,958+9.5% | Added |
| Velan Capital Investment Management LP | 2,844,652 | $10.9M | 6.66% | +10,000+0.4% | Added |
| Vanguard Capital Management LLC | 2,300,133 | $8.79M | 0.00% | +181,115+8.5% | Added |
| Blackstone Group Inc. | 2,265,514 | $8.65M | 0.03% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 2,220,000 | $8.48M | 0.16% | +2,220,000 | New |
| Sio Capital Management, LLC | 1,921,872 | $7.34M | 1.26% | −47,967−2.4% | Reduced |
| Acorn Capital Advisors, LLC | 1,752,115 | $6.69M | 1.83% | 00.0% | Unchanged |
| Integral Health Asset Management, LLC | 1,500,000 | $5.73M | 0.24% | −250,000−14.3% | Reduced |